Stellate Ganglion Block for Treating Post-COVID-19 Posttraumatic Stress Disorder

Posttraumatic stress disorder (PTSD) has emerged as a significant neuropsychiatric complication in the aftermath of COVID-19, particularly among individuals with severe illness. Conventional treatments often fall short for these patients, highlighting the need for novel therapeutic approaches. Stellate ganglion block (SGB), a sympathetic nerve block targeting the cervical sympathetic chain, has shown promise in alleviating PTSD symptoms by modulating autonomic dysregulation.

We report the case of a man with treatment-resistant PTSD following a COVID-19 infection in 2020. After unsuccessful trials of therapy and pharmacologic interventions, the patient underwent a series of bilateral SGBs 2 weeks apart. The procedures were performed under fluoroscopic guidance using a local anesthetic and corticosteroid combination. At the 2-month follow-up, the patient reported marked improvement in mood, anxiety, and panic symptoms, indicating a sustained clinical benefit.

Our case supports the growing evidence for SGB as a potential treatment for post-COVID-19 PTSD, particularly in patients unresponsive to conventional therapies. While encouraging, this finding underscores the need for further research to establish efficacy, safety, and patient selection criteria in broader populations.